Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets extend losses
Wed, 18 Mar 03:30 pm

Indian markets extended losses as selling pressure persisted among few sectoral indices. While BSE-Sensex fell over 100 points, NSE-Nifty fell over 30 points. Stocks from the capital goods and auto sectors lost the maximum during today's trading session, while other sectors traded with modest profits. S&P Midcap and S&P Smallcap stocks outperformed the market, gained 0.3% and 0.4%, respectively.

Commodities extended their weakness over the second session. Gold prices, per 10 grams, fell 0.3% or Rs 63 at Rs 25,500 levels while Silver prices, per kilogram, fell 0.4% or Rs 120 and is trading at Rs 35,200 levels. Crude oil prices continued to freefall. Per barrel, crude oil price fell over 3%. The value of Indian Rupee against the US Dollar stood at Rs 62.71 as investors await clarity or a decision on increasing the interest rates.

European stocks continued to trade mixed as German stock exchange, DAX lost about 0.3%, while the French Stock exchange, CAC and FTSE continued to trade with modest gains of 0.6% and 0.2%, respectively.

Auto companies continued to trade with over 0.7% losses led by Tata Motors. Shares of Tata Motors fell over 2% after the company reported dismal sales for JLR in the month of February. Sales of JLR fell 1% YoY. In terms of units, Tata Motors sold 38,541 units of JLR. Another two brands under Tata Motors also provided disappointing sales figures. Sales of Jaguar dropped 3% to 6,448 units while sales of Land Rover came down 1% to 32,093 units. Overall sales volume of Tata Motors remained below expectations. Sales volume of Tata Motors fell 6% YoY to 28,689 units. On the positive side, volumes in North America, Europe and the United Kingdom increased 11%, 2% and 14%, respectively.

Pharma stocks have been trading with moderate gains, however, shares of Wockhardt fell over 2% as it failed to receive a patent for a drug that is used to cure osteoarthritis. According to a leading financial source, the patent office rejected the drug on the basis that it did not offer any extra incentive step. The company had filed that drug for a patent claiming that the drug helps in softening stool by 25% compared to the one offered by 50 mg Diacerein which is sold under the name of Art 50.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets extend losses". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.